Skip to main content

Table 1 Gestational age and maternal malaria infection status at delivery

From: Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study

  AL ASAQ MQAS DHAPQ p-valuea
N   N   N   N   
Maternal age median (IQR) 881 21 (18–26) 842c 22 (19–27) 850c 22 (19–27) 855 20 (18–25) 0.67
Gestational age (week) median (IQR) 804 38 (36–38) 729 38 (38–40) 733 38 (36–40) 709 38 (36–38) 0.30
Gravidity n (%) 880   842   850   855   0.55
 1st pregnancy   319 (36.3)   315 (37.4)   278 (32.7)   343 (40.1)  
 2nd pregnancy   204 (23.2)   187 (22.2)   201 (23.7)   216 (25.3)  
 3rd or more   357 (40.6)   340 (40.4)   371 (43.7)   296 (34.6)  
Malaria prevalence (peripheral blood) n (%) 829 120 (14.5) 756 95 (12.6) 752 123 (16.4) 748 75 (10.0) 0.21
Parasite density; median (IQR) 120 1560 (440–6804) 95 1800 (320–8220) 123 1729 (561–9000) 75 2320 (480–8960) 0.09
 % ≤ 2000/µL (n)   55.0 (66)   53.7 (51)   52.0 (64)   46.7 (35)  
 % > 2000/µL (n)   45.0 (54)   46.3 (44)   48.0 (59)   53.3 (40)  
Gametocyte carriage n (%) 829 3 (0.4) 756 4 (0.5) 752 4 (0.5) 748 2 (0.3) 0.89
Maternal Hb median (IQR) 828 11.2 (10.1–12.2) 757 11.5 (10.4–12.4) 752 11.3 (10.3–12.3) 749 11.2 (10.3–12.2) 0.30
Placenta Malaria n (%)b 711   655   674   664   
 Acute infection   7 (1.0)   14 (2.1)   13 (1.9)   11 (1.7)  
 Chronic infection   191 (26.9)   168 (25.6)   177 (26.3)   171 (25.8)  
 Past infection   444 (62.4)   382 (58.3)   398 (59.1)   409 (61.6)  
 No infection   69 (9.7)   91 (13.9)   86 (12.8)   73 (11.0)  
  1. aAdjusted by country
  2. bThe proportion of current (acute and chronic) and past infection vs. no infection, adjusted for country, p = 0.47. Proportion of acute and chronic infection vs. past or no infection, adjusted for country p = 0.52
  3. cOne woman randomized to the ASAQ group was treated with MQAS; in the safety analysis this woman was included in the MQAS group